Leukemia, Myelomonocytic, Chronic: all 340 studies

Page 1 of 4. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.

• Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic LeukemiaNot yet recruitingNCT07852494Not applicable
• A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid MalignanciesNot yet recruitingNCT07719348Phase 1/2
• Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic LeukemiaRecruitingNCT07588594Not applicable
• Cohort of Patients With Chronic Myelomonocytic LeukemiaRecruitingNCT07512882
• Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic LeukemiaNot yet recruitingNCT07468916Phase 2
• Therapeutic RSK1 Targeting in Myeloid MalignanciesRecruitingNCT07379125Phase 1
• TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCTRecruitingNCT07302776Phase 1
• Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationRecruitingNCT07249346Phase 2
• Screening Study for KIT D816V Mutated Mast Cell Disease in Select PopulationsRecruitingNCT07143669
• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingNCT07128381Phase 1/2
• The Kinetics Profiling of Immune Reconstitution and Clinical OutcomesNot yet recruitingNCT07113730
• Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaRecruitingNCT07071155Early Phase 1
• Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid CancerRecruitingNCT07046078Phase 2
• Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic LeukemiaRecruitingNCT07033598Phase 2
• A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasRecruitingNCT06994676Phase 1
• A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)RecruitingNCT06950034Phase 1
• Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseRecruitingNCT06928662Phase 1/2
• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
• Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms PatientsNot yet recruitingNCT06900088Phase 2
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationRecruitingNCT06859424Phase 2
• Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningRecruitingNCT06815003Phase 2
• Oral-ATO for TP53-mutated Myeloid MalignanciesRecruitingNCT06778187Phase 2
• Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
• Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal HematopoiesisRecruitingNCT06691217Phase 2
• IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)RecruitingNCT06647862Phase 3
• A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.RecruitingNCT06566742Phase 2
• Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantRecruitingNCT06543381Phase 1
• Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaRecruitingNCT06523556Phase 1/2
• Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)RecruitingNCT06462365Phase 1
• Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive ChemotherapyRecruitingNCT06439199
• Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) TrialRecruitingNCT06355583Phase 2
• Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 1
• Pacritinib in CMMLRecruitingNCT06159491Phase 1/2
• Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementRecruitingNCT06111612
• Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMMLRecruitingNCT05970822Phase 1
• Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLRecruitingNCT05807932Phase 1/2
• A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLRecruitingNCT05641259Phase 1
• Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingNCT05636514Phase 1
• Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAMLRecruitingNCT05584761Phase 1/2
• Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap NeoplasmsRecruitingNCT05549661Phase 1
• Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological MalignanciesRecruitingNCT05488548Phase 1
• Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLRecruitingNCT05184842Phase 2Results posted
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
• Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
• (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingNCT04996875Phase 2
• Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
• Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingNCT04708054Phase 2/3
• Study to Evaluate the Safety and Tolerability of EP0042RecruitingNCT04581512Phase 1/2
• CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingNCT04375631Phase 1
• A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSRecruitingNCT04358393Phase 1/2
• A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingNCT04256317Phase 2/3
• A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaRecruitingNCT04239157Phase 2
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
• Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingNCT04140487Phase 1/2
• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)Enrolling by invitationNCT04093570Phase 2
• Combining Active and Passive DNA HypomethylationRecruitingNCT03999723Phase 2
• Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) TransplantRecruitingNCT03964506Early Phase 1
• CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaRecruitingNCT03896269Phase 1
• Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT03850574Phase 1/2
• Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationRecruitingNCT03683433Phase 2
• 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromeRecruitingNCT03670966Phase 1/2
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingNCT03418038Phase 2
• Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeRecruitingNCT03383575Phase 2
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantRecruitingNCT03326921Phase 1
• Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)RecruitingNCT03280888
• 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute LeukemiaRecruitingNCT03128034Phase 1/2
• Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT02760238
• Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
• Registry of Older Patients With CancerRecruitingNCT01137825
• A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsTerminatedNCT05787496Phase 1Results posted
• AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic LeukemiaTerminatedNCT05209152Phase 1Results posted
• A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)TerminatedNCT05038800Phase 1Results posted
• A Study of E7820 in People With Bone Marrow (Myeloid) CancersCompletedNCT05024994Phase 2Results posted
• Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMMLCompletedNCT04842604Phase 3Results posted
• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
• Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway MutationsActive, not recruitingNCT04409639Phase 2Results posted
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)TerminatedNCT04266301Phase 3Results posted
• Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseCompletedNCT04146038Phase 2Results posted
• Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMMLTerminatedNCT03922100Phase 1/2Results posted
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver ProblemsCompletedNCT03814005Phase 1Results posted
• Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
• Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 ExpansionActive, not recruitingNCT03722407Phase 2Results posted
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT03358719Phase 1Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLCompletedNCT03306264Phase 3Results posted
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT03289910Phase 2Results posted
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT03268954Phase 3Results posted
• IGF-MTX Conjugate in the Treatment of Myelodysplastic SyndromeTerminatedNCT03175978Phase 1/2Results posted
• Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating AgentTerminatedNCT03146871Phase 2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedNCT03072043Phase 1/2Results posted
• Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeCompletedNCT03047993Phase 1/2Results posted
• Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTCompletedNCT03018223Phase 1Results posted
• Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsCompletedNCT02907359Phase 3Results posted
• Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaCompletedNCT02807272Phase 2Results posted
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsCompletedNCT02756572Phase 2Results posted
• Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantCompletedNCT02684162Phase 2Results posted

← Leukemia, Myelomonocytic, Chronic overview